Related Experiment Video
Updated: Mar 27, 2026
09:01
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
8.4K
Novel insights into human respiratory syncytial virus-host factor interactions through integrated proteomics and
Clyde Dapat1, Hitoshi Oshitani1
1a Department of Virology , Tohoku University Graduate School of Medicine , Sendai , Miyagi Prefecture , Japan.
Expert Review of Anti-Infective Therapy
|January 14, 2016
Summary
New research identifies host factors targeted by respiratory syncytial virus (RSV). This study explores drug repositioning for potential RSV infection treatments, addressing the need for novel therapeutic strategies against this common respiratory virus.
Area of Science:
- Virology
- Computational Biology
- Pharmacology
Background:
- Respiratory syncytial virus (RSV) poses a significant health challenge due to limited vaccines and antiviral therapies.
- Identifying host factors essential for viral replication is crucial for developing new treatment strategies.
Purpose of the Study:
- To construct a comprehensive virus-host interaction network by integrating proteome and transcriptome data.
- To identify host factors targeted by RSV and explore potential drug repositioning opportunities.
Main Methods:
- Integration of existing microarray and proteomics datasets related to RSV infection.
- Construction of a virus-host interaction network using integrated data.
- Interrogation of the network to identify viral targets and screening of the DrugBank database for potential therapeutic compounds.
Main Results:
- A comprehensive network detailing RSV-host interactions was successfully constructed.
- Key host factors targeted by the virus were identified through network analysis.
- A list of existing drugs interacting with these host factors was generated, suggesting potential for repurposing.
Conclusions:
- The study provides a network-based approach to understand RSV-host interactions.
- Identified host factors and potential drug candidates offer promising avenues for novel RSV therapeutic strategies.
- Drug repositioning presents a viable strategy to accelerate the development of treatments for RSV infections.
